1.Study for the Efficacy and the Safety of Immediate Breast Reconstruction Following a Curative Mastectomy.
Jung Han YOON ; Young Jong JAEGAL ; Sang Young CHUNG
Journal of the Korean Surgical Society 1998;54(6):803-809
Immediate reconstruction of a breast after a curative mastectomy is a good alternative to a breast conserving operation and can be accomplished without altering the cancer-ablative purpose. The transversus rectus abdominis myocutaneous(TRAM) flap has proven to be the most useful autogenous tissue for restoring a breast. We evaluated 14 cases of breast cancer in which the patient underwent immediate TRAM flap reconstruction by the same surgeons who had performed the curative mastectomy. Immediate TRAM reconstruction was performed safely in all stages of breast cancer, although the majority of the patients were in stage 2. Partial necrosis of the myocutaneous flap(1 case), partial necrosis of the breast skin(1 case), hematoma(2 cases), and wound infection(1 case) developed as postoperative complications and were controlled by conservative management. Postoperative chemotherapy and chemoradiation therapy were performed in 7 cases and 4 cases, respectively, without any discernible adverse influence on the myocutaneous flap. The majority of the patients were satisfied with the reconstructed breast. Based on these results, we suggest that immediate breast reconstruction using the pedicled TRAM flap can be accomplished by the surgeon who performed the mastectomy: and will enhance cosmetic appearance without any adverse impact on curabilitly.
Breast Neoplasms
;
Breast*
;
Drug Therapy
;
Female
;
Humans
;
Mammaplasty*
;
Mastectomy*
;
Myocutaneous Flap
;
Necrosis
;
Postoperative Complications
;
Rectus Abdominis
;
Wounds and Injuries
2.Therapeutic effect of acupuncture on cisplatin-induced nausea and vomiting.
Chinese Acupuncture & Moxibustion 2009;29(1):3-6
OBJECTIVETo observe therapeutic effect of acupuncture combined with antiemetic on cisplatin-induced nausea and vomiting.
METHODSBy using paired, cross-controlled trial design, 66 cases of chemotherapy were divided into group A and B, 33 cases in each group. For the group A, chemotherapy, tropisetron and acupuncture therapy were adopted in the first chemotherapy cycle and the same chemotherapy program, tropisetron and sham acupuncture were used in the next cycle. For the group B, chemotherapy, tropisetron and sham acupuncture were given in the first chemotherapy cycle and the same chemotherapy program, tropisetron and acupuncture therapy were applied in the next cycle. Zusanli (ST 36), Neiguan (PC 6) and Gongsun (SP 4) and auricular point Wei (stomach) were selected for acupuncture therapy, and the points at 3 cm lateral to Zusanli (ST 36) , Neiguan (PC 6) and Gongaun (SP 4) and auricular point corresponding to scapha level were selected for sham acupuncture. Acupuncture treatment or sham-acupuncture was given for 6 consecutive days, once each day and antiemetic tropisetron 5 mg was given to the two groups as basic antiemetic prophylaxis for 6 days, once daily. The therapeutic effects on nausea and vomiting in the 6 days were compared between the acupuncture group and the sham-acupuncture group in the two chemotherapeutic cycles.
RESULTSThe effective rates for nausea in the 2nd day and the 4th day were 87.1% and 79.0% in acupuncture group, which were superior to 59.4% and 57.8% in the sham-acupuncture group, respectively (both P < 0.05); and the therapeutic effects on vomiting in the 3rd-6th day in the acupuncture group were better than those in the sham-acupuncture group (P < 0.05).
CONCLUSIONAcupuncture combined with antiemetic can effectively decrease the incidence and degree of cisplatin-induced delayed nausea and vomiting. The effect of acupuncture is better than that of sham acupuncture.
Acupuncture Points ; Acupuncture Therapy ; Adolescent ; Adult ; Aged ; Antiemetics ; administration & dosage ; Breast Neoplasms ; complications ; drug therapy ; Cisplatin ; adverse effects ; therapeutic use ; Female ; Humans ; Lung Neoplasms ; complications ; drug therapy ; Male ; Middle Aged ; Nausea ; drug therapy ; etiology ; therapy ; Vomiting ; drug therapy ; etiology ; therapy
3.Association between cancer related fatigue and social support in patients after breast cancer chemotherapy in Changsha.
Pinglan JIANG ; Shuhong WANG ; Dongmei JIANG ; Lingli YU ; Lili TANG ; Juan LAI
Journal of Central South University(Medical Sciences) 2011;36(9):844-848
OBJECTIVE:
To explore the association between the cancer related fatigue and social support in breast cancer patients after chemotherapy.
METHODS:
According to the uniform inclusive and exclusive criteria, 396 breast cancer patients after chemotherapy were sampled randomly from 4 hospitals in Changsha and investigated on the spot by cancer fatigue scale and social support scale.
RESULTS:
The levels of social support, subjective support, Objective support, and utilization of support of the breast cancer patients after chemotherapy were 36.63±7.80, 21.05±4.67, 8.45±3.06, and 7.13±2.10, respectively, which were lower than the normal level, with significant difference(P<0.001). There was a negative correlation between each fatigue dimension and social support, subjective support, Objective support, and utilization of support (P<0.05 or P<0.001).
CONCLUSION
The social support system in patients with breast cancer after chemotherapy is poor. There is a negative correlation between the social support system and cancer related fatigue.
Adult
;
Aged
;
Antineoplastic Agents
;
therapeutic use
;
Breast Neoplasms
;
complications
;
drug therapy
;
Carcinoma, Ductal, Breast
;
drug therapy
;
psychology
;
China
;
Fatigue
;
etiology
;
psychology
;
Female
;
Humans
;
Middle Aged
;
Social Support
4.Relation between Chinese Medical Constitutions and Chemotherapy-induced Leucopenia in Breast Cancer Patients: a Clinical Study.
Yi LIU ; Qing-hua CHEN ; Ye SUN ; Yun CAI ; Rui WANG ; Ping-ping HAN ; Zhe ZHANG ; Rui WANG ; Feng YE
Chinese Journal of Integrated Traditional and Western Medicine 2015;35(6):664-667
OBJECTIVETo analyze the relationship between Chinese medical constitutions and chemotherapy-induced leucopenia (CIL) of primary breast cancer patients.
METHODSTotally 306 breast cancer patients undergoing adjunctive chemotherapy for the 1st time, and effective 291 breast cancer patients were recruited in this study.Nine Basic Constitutional Scale was used before first chemotherapy. Chinese medical constitutions were classified and quantitatively scored. The highest grading for any item of adverse reactions in each case during the whole chemotherapy course was recorded after chemotherapy. Data were statistically analyzed using SPSS16.0.
RESULTSThere was no significant difference in CIL between different chemotherapy regimens and various Chinese medical constitutions of breast cancer patients (P > 0.05). Yang deficiency constitution is one risk factor for CIL. The higher the score of yang deficiency constitution, the more severe the CIL.
CONCLUSIONSYang deficiency constitution was correlated with the degree of CIL. The higher the score of yang deficiency constitution, the greater the risk of III-IV grade CIL in breast cancer patients.
Breast Neoplasms ; complications ; drug therapy ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Humans ; Leukopenia ; chemically induced ; Medicine, Chinese Traditional ; Yang Deficiency
5.Adenomatous polyp--cause of postmenopausal bleeding in a breast cancer patient treated with tamoxifen.
Patankar Z JAHOORAHMAD ; Kashid YATINDRA ; Vyas J JITENDRA
Singapore medical journal 2003;44(7):359-359
We present a case of adenomatous polyp with degenerative changes causing abnormal postmenopausal bleeding in a patient who was treated with adjuvant therapy of Tamoxifen for breast cancer after surgery (Modified Radical Mastectomy). The association with prolonged unopposed estrogen--like stimulation with Tamoxifen as a possible factor in this development has been discussed. Until further cases are reported, it would seem imperative to advise all women who are to be treated with Tamoxifen for breast malignancy to have a pelvic examination before such treatment with strict follow up at regular intervals later on. Abnormal bleeding may also be the result of Tamoxifen stimulation and endometrial biopsy may be necessary in these patients should abnormal bleeding occur. Surgical exploration for enlarging leiomyomas or abnormal bleeding will still be necessary to ensure that malignancy is not present, but the pre-operative diagnosis will be less alarming.
Adenomatous Polyps
;
complications
;
etiology
;
Aged
;
Breast Neoplasms
;
drug therapy
;
surgery
;
Endometrial Neoplasms
;
complications
;
etiology
;
Female
;
Humans
;
Mastectomy, Modified Radical
;
Postmenopause
;
Tamoxifen
;
therapeutic use
;
Uterine Hemorrhage
;
etiology
7.Anti-rheumatic drug iguratimod (T-614) alleviates cancer-induced bone destruction via down-regulating interleukin-6 production in a nuclear factor-κB-dependent manner.
Yue SUN ; Da-Wei YE ; Peng ZHANG ; Ying-Xing WU ; Bang-Yan WANG ; Guang PENG ; Shi-Ying YU
Journal of Huazhong University of Science and Technology (Medical Sciences) 2016;36(5):691-699
Cytokines are believed to be involved in a "vicious circle" of progressive interactions in bone metastasis. Iguratimod is a novel anti-rheumatic drug which is reported to have the capability of anti-cytokines. In this study, a rat model was constructed to investigate the effect of iguratimod on bone metastasis and it was found that iguratimod alleviated cancer-induced bone destruction. To further explore whether an anti-tumor activity of iguratimod contributes to the effect of bone resorption suppression, two human breast cancer cell lines MDA-MB-231 and MCF-7 were studied. The effect of iguratimod on tumor proliferation was detected by CCK-8 assay and flow cytometry. The effects of iguratimod on migration and invasion of cancer cells were determined by wound-healing and Transwell assays. Results showed that high dose (30 μg/mL) iguratimod slightly suppressed the proliferation of cancer cells but failed to inhibit their migration and invasion capacity. Interestingly, iguratimod decreased the transcription level of IL-6 in MDA-MB-231 cells in a concentration-dependent manner. Moreover, iguratimod partially impaired NF-κB signaling by suppressing the phosphorylation of NF-κB p65 subunit. Our findings indicated that iguratimod may alleviate bone destruction by partially decreasing the expression of IL-6 in an NF-κB-dependent manner, while it has little effect on the tumor proliferation and invasion.
Animals
;
Apoptosis
;
drug effects
;
Bone Neoplasms
;
complications
;
drug therapy
;
pathology
;
secondary
;
Bone Resorption
;
complications
;
drug therapy
;
pathology
;
Breast Neoplasms
;
complications
;
drug therapy
;
genetics
;
pathology
;
Carcinogenesis
;
drug effects
;
Cell Movement
;
drug effects
;
Cell Proliferation
;
drug effects
;
Chromones
;
administration & dosage
;
Female
;
Humans
;
Interleukin-6
;
biosynthesis
;
genetics
;
MCF-7 Cells
;
Neoplasm Invasiveness
;
genetics
;
pathology
;
Rats
;
Sulfonamides
;
administration & dosage
;
Transcription Factor RelA
;
biosynthesis
;
genetics
8.Oral etoposide monotherapy is effective for metastatic breast cancer with heavy prior therapy.
Peng YUAN ; Bing-he XU ; Jia-yu WANG ; Fei MA ; Ying FAN ; Qing LI ; Pin ZHANG
Chinese Medical Journal 2012;125(5):775-779
BACKGROUNDTreatment option for metastatic breast cancer (MBC) patients pre-treated with chemotherapy is limited. Oral etoposide has shown some promises in these patients. However, patients who received heavy prior chemotherapy may have poor tolerance to prolonged oral etoposide exposure. This study is a single-arm clinical trial that evaluates the efficacy and safety of short-term oral etoposide in Chinese patients with MBC who had received heavy prior therapy.
METHODSMBC patients receiving at least two chemotherapy regimens prior to the enrollment were treated with repeated cycles of oral etoposide (60 mg×m(-2)×d(-1) on days 1-10, followed by 11 days of rest). The primary end point was the progression free survival (PFS). The secondary end points were objective response rate (ORR), clinical benefit rate (CBR), overall survival (OS), and toxicity profiles.
RESULTSThirty-two patients received 230 cycles of oral etoposide with a median of 6 cycles (range, 2-20 cycles) per patient. Eight patients (25%) had partial response (PR) and 14 patients achieved stable disease (SD). The ORR was 25%. Nine patients achieved SD for more than 24 weeks and CBR was 53%. The median PFS and OS were 5 (range, 1.5-17.0 months) and 16 months (range, 3.0-51.0 months), respectively. The patients who achieved clinical benefit had longer survival time than those who did not (25.0 versus 11.0 months, P<0.01). Among the 16 patients who received more than four regimens prior to this study, four patients achieved PR and four achieved SD for more than 24 weeks, with a CBR of 50%. The most common hematologic adverse events were anemia (43.8%) and neutropenia (38.5%). Nausea/vomiting (75.0%) and alopecia (62.5%) were the most frequent non-hematologic toxicities.
CONCLUSIONOral etoposide is effective and well tolerated in Chinese women with heavily pretreated MBC.
Administration, Oral ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms ; complications ; drug therapy ; Drug Administration Schedule ; Etoposide ; administration & dosage ; therapeutic use ; Female ; Humans ; Middle Aged ; Young Adult
10.Clinical trial on ibandronate in patients with tumor-associated hypercalcemia.
Tao WANG ; San-tai SONG ; Ze-fei JIANG ; Shou-geng BIAN ; Ya-jie WANG ; Li-qing LI ; Jun ZHU
Chinese Journal of Oncology 2004;26(12):739-741
OBJECTIVEIbandronate, a third generation bisphosphonate, inhibits bone resorption in human and animal studies. This study is to evaluate the efficacy and safety of ibandronate as a single agent in patients with tumor-associated hypercalcemia.
METHODSAn open, multicenter, non-controlled clinical trial was conducted in 22 patients. The patients received 2 mg ibandronate intravenously if the corrected calcium was less than 3.0 mmol/L but more than 2.7 mmol/L; they received 4 mg ibandronate iv if corrected calcium was more than 3.0 mmol/L.
RESULTSThere was 100% efficacy in these two dose groups but the calcium correcting effect was more pronounced in the 4-mg dose group than the 2-mg dose group. The most common adverse reactions were fever and skin itching with an incidence of 4.5%.
CONCLUSIONIbandronate is active in patients with tumor-associated hypercalcemia and the adverse effects are well tolerated.
Bone Neoplasms ; complications ; secretion ; Breast Neoplasms ; complications ; pathology ; Calcium ; blood ; Diphosphonates ; administration & dosage ; therapeutic use ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Fever ; chemically induced ; Humans ; Hypercalcemia ; blood ; drug therapy ; etiology ; Lung Neoplasms ; complications ; pathology ; Male ; Middle Aged ; Multiple Myeloma ; complications ; Phosphorus ; blood ; Pruritus ; chemically induced